Oralead Pharma
The company website confirms the Macoral® / Simgut® platform and collaboration with BrightGene. The pipeline image reviewed is historical; current clinical stages require confirmation.
Corporate information
- Company entity
- 深圳奥礼生物科技有限公司
- Headquarters / principal office
- ShenzhenSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters. ↗
- Founded
- 2022 ↗
- Ownership / capital status
- PrivatePre-Series A (latest disclosure identified) ↗
- Official corporate reference
- https://www.oralead.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2024-01-30 · Pre-Series A · Tens of millions of RMB (exact amount not disclosed) ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Public evidence snapshot
The company positions Macoral® as an oral macromolecule delivery platform, supported by its Simgut® in vitro evaluation system.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.